Related Experiment Video

Updated: May 24, 2026

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

Long-term treatment of metastatic colorectal cancer with panitumumab

Miriam López-Gómez1, María Merino, Enrique Casado

  • 1Clinical Oncology, Infanta Sofía Hospital, San Sebastián de los Reyes, Madrid.

Clinical Medicine Insights. Oncology
|March 13, 2012
PubMed

Insights

Panitumumab, an anti-epidermal growth factor receptor (EGFR) therapy, offers significant benefits for colorectal cancer patients with metastases. This fully human monoclonal antibody is a key treatment option for advanced disease.

Area of Science:

  • Oncology
  • Medical research

Background:

  • Colorectal cancer (CRC) is a major global health concern, causing numerous cancer-related deaths.
  • Over 30% of CRC patients are diagnosed with metastatic disease, necessitating systemic chemotherapy.
  • Targeted therapies, particularly anti-epidermal growth factor receptor (EGFR) agents, have emerged as crucial treatment modalities.

Purpose of the Study:

  • To evaluate the efficacy and benefits of panitumumab in treating colorectal cancer.
  • To highlight the role of fully human monoclonal antibodies in cancer therapy.

Main Methods:

  • Clinical studies and trials involving panitumumab were reviewed.
  • Data on patient outcomes with metastatic colorectal cancer treated with panitumumab were analyzed.

Main Results:

  • Panitumumab, a fully human IgG2 monoclonal antibody, has demonstrated significant benefits in treating colorectal cancer.
  • The drug shows particular efficacy in patients with metastatic disease.

Conclusions:

  • Panitumumab represents an important therapeutic option for patients with metastatic colorectal cancer.
  • Targeted therapies like panitumumab are advancing the treatment landscape for advanced colorectal cancer.
Keywords:
anti-EGFRchemotherapy agentscolorectal cancermetastasis

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...